Eton Pharmaceuticals, Inc. Common Stock
ETON US29772L1089
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -47% | -40% | 52% | 190% | -9% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Gruber James R. CFO |
16.02 USD |
2,631 Sold |
42,149 USD |
19/08/2025 | 20/08/2025 |
| Gruber James R. CFO |
16.16 USD |
39,082 Sold |
631,565 USD |
19/08/2025 | 19/08/2025 |
| Krempa David CBO |
14.73 USD |
10,223 Sold |
150,585 USD |
12/06/2025 | 16/06/2025 |
| Krempa David CBO |
14.73 USD |
10,223 Sold |
150,585 USD |
12/06/2025 | 16/06/2025 |
| Krempa David CBO |
14.77 USD |
6,800 Sold |
100,436 USD |
12/06/2025 | 13/06/2025 |
| Krempa David CBO |
14.77 USD |
6,800 Sold |
100,436 USD |
12/06/2025 | 13/06/2025 |
| Krempa David CBO |
14.92 USD |
16,977 Sold |
253,297 USD |
12/06/2025 | 12/06/2025 |
| Krempa David CBO |
14.92 USD |
16,977 Sold |
253,297 USD |
12/06/2025 | 12/06/2025 |
| Opaleye Management Inc. O |
15.82 USD |
5,000 Bought |
79,120 USD |
10/06/2025 | 10/06/2025 |
| Opaleye Management Inc. O |
15.82 USD |
2,930 Bought |
46,364 USD |
10/06/2025 | 10/06/2025 |